CYX Calyx Ventures Inc

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) ("Calyx" or the "Company") announces
that it has entered into an agreement with BDC Capital Inc. and Agrisoma
Biosciences Inc. ("Agrisoma") pursuant to which Calyx has agreed to waive its
pre-emptive right in order to allow a third party to finance Agrisoma. The
proposed Agrisoma financing, if it were to proceed as proposed and without
Calyx's participation will, upon closing, dilute Calyx's interest in Agrisoma
from 49.96% to approximately 29%. Following an evaluation by an Independent
Committee of Calyx's board of directors, it was determined that in Calyx's view,
Agrisoma's business had not progressed as expected, and no options for financing
Agrisoma could be found that would be satisfactory to shareholders of Calyx.


Additionally, intellectual property ("IP") which was exclusively licensed to
Agrisoma by Calyx is no longer under exclusive license to Agrisoma. With the IP
reverting to Calyx, Calyx is now able to license and utilize its IP in other
agricultural sector opportunities that it is currently investigating. The unique
and powerful features of this technology provide clear advantages for the
development of plant-based products. Calyx is in discussions and pursuing a
number of new business opportunities in the agriculture and agri-pharmaceutical
sectors including the MMPR (Marijuana for Medical Purposes Regulations) and
marijuana biotech where we can bring our depth of agriculture capacities.


Accordingly, the Calyx board has determined to cancel the dilutive non-brokered
private placement for the issuance of up to 35 million units at a price of six
cents per unit for cash proceeds of up to $2.1-million previously announced on
March 31, 2014.


About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
which is developing early stage agriculture ventures. Calyx brings its depth of
experience, capital and other capacity, including its proprietary intellectual
property, to enhance plant yields. In addition to Calyx's shareholding in
Agrisoma Biosciences Inc., a company which is producing a non-food energy
feedstock crop for bioenergy, Calyx is pursuing agri-pharmaceutical
opportunities in the MMPR (Marijuana for Medical Purposes Regulations) and the
agri-tech space. The medical marijuana industry is in its infancy and is an
emerging multibillion-dollar opportunity undergoing significant regulatory and
legal reform which offers strong growth opportunities to early participants. For
further information about Calyx, please visit www.calyxbio.com.


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control.


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect.


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604-649-5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Investor Relations:
Keir Reynolds
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From Apr 2024 to May 2024

Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From May 2023 to May 2024